To cite this paper use one of the standards below:
Chikungunya (CHIK) is a mosquito-borne viral disease identified in several 100 countries. In Brazil, this disease accounted for 233,225 cases and 134 deaths, in the first six months of 2024. CHIK is characterized by abrupt high fever, headache, arthralgia, myalgia, maculopapular rash, and neurological complications. Recent findings indicate that skeletal muscle cell infection may be crucial in directing disease progression. In addition, currently, there is no specific treatment for myalgia resulting from CHIK. Thus, given that cannabinoids have shown potential as anti-inflammatory and antiviral agents in experimental models of SARS-CoV-2, this study aimed to evaluate the effects of the synthetic cannabinoids, Arachidonoyl 2’-Chloroethylamide (ACEA) and Hemopressin (Hp), agonist and reverse agonist of the CB1 receptor, respectively, on human skeletal muscle immortalized myoblasts (CL48), infected with Chikungunya virus (CHIKV). The CL48 cells were treated with ACEA or Hp, before or after CHIK infection at a multiplicity of infection (MOI) of 0.01, 0.1, or 1.0. Still, the expression of CB1 receptors was higher in the untreated CHIK-infected myoblasts. Besides, only the positive control greater than a ten-fold higher MOI exhibited a cytopathic effect and decreased cell viability. After pre-treatment with the Hp for 1 hour, IL-6, IL-8, and IL-23 expressions were reduced (P < 0.05). Plaque assays indicated that both pre-treatment and post-treatment led to higher levels of viral particle forming units (PFU). Then, further research is necessary on the potential immunosuppressive effects of cannabinoids, their antiviral effects in muscle cells, and the strategic use of cannabinoid administration in murine models during the chronic phase of the disease, when the viremia has ceased, but inflammation persists.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper